Literature DB >> 29050751

Fibrosis-Related Gene Expression in Single Ventricle Heart Disease.

Stephanie J Nakano1, Austine K Siomos1, Anastacia M Garcia1, Hieu Nguyen1, Megan SooHoo1, Csaba Galambos2, Karin Nunley1, Brian L Stauffer3, Carmen C Sucharov4, Shelley D Miyamoto5.   

Abstract

OBJECTIVE: To evaluate fibrosis and fibrosis-related gene expression in the myocardium of pediatric subjects with single ventricle with right ventricular failure. STUDY
DESIGN: Real-time quantitative polymerase chain reaction was performed on explanted right ventricular myocardium of pediatric subjects with single ventricle disease and controls with nonfailing heart disease. Subjects were divided into 3 groups: single ventricle failing (right ventricular failure before or after stage I palliation), single ventricle nonfailing (infants listed for primary transplantation with normal right ventricular function), and stage III (Fontan or right ventricular failure after stage III). To evaluate subjects of similar age and right ventricular volume loading, single ventricle disease with failure was compared with single ventricle without failure and stage III was compared with nonfailing right ventricular disease. Histologic fibrosis was assessed in all hearts. Mann-Whitney tests were performed to identify differences in gene expression.
RESULTS: Collagen (Col1α, Col3) expression is decreased in single ventricle congenital heart disease with failure compared with nonfailing single ventricle congenital heart disease (P = .019 and P = .035, respectively), and is equivalent in stage III compared with nonfailing right ventricular heart disease. Tissue inhibitors of metalloproteinase (TIMP-1, TIMP-3, and TIMP-4) are downregulated in stage III compared with nonfailing right ventricular heart disease (P = .0047, P = .013 and P = .013, respectively). Matrix metalloproteinases (MMP-2, MMP-9) are similar between nonfailing single ventricular heart disease and failing single ventricular heart disease, and between stage III heart disease and nonfailing right ventricular heart disease. There is no difference in the prevalence of right ventricular fibrosis by histology in subjects with single ventricular failure heart disease with right ventricular failure (18%) compared with those with normal right ventricular function (38%).
CONCLUSIONS: Fibrosis is not a primary contributor to right ventricular failure in infants and young children with single ventricular heart disease. Additional studies are required to understand whether antifibrotic therapies are beneficial in this population.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  collagen; congenital heart disease; hypoplastic left heart syndrome; matrix metalloproteinases (MMPs); pediatric heart failure; tissue inhibitors of metalloproteinases (TIMPs)

Mesh:

Substances:

Year:  2017        PMID: 29050751      PMCID: PMC5705574          DOI: 10.1016/j.jpeds.2017.08.055

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  43 in total

1.  Histopathologic findings in explanted heart tissue from patients with end-stage idiopathic dilated cardiomyopathy.

Authors:  N de Leeuw; D J Ruiter; A H Balk; N de Jonge; W J Melchers; J M Galama
Journal:  Transpl Int       Date:  2001-09       Impact factor: 3.782

2.  Interstitial fibrosis in the heart: differences in extracellular matrix proteins and matrix metalloproteinases in end-stage dilated, ischaemic and valvular cardiomyopathy.

Authors:  E Herpel; M Pritsch; A Koch; T J Dengler; P Schirmacher; Ph A Schnabel
Journal:  Histopathology       Date:  2006-05       Impact factor: 5.087

3.  Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.

Authors:  J T Peterson; H Li; L Dillon; J W Bryant
Journal:  Cardiovasc Res       Date:  2000-05       Impact factor: 10.787

4.  Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.

Authors:  C V Thomas; M L Coker; J L Zellner; J R Handy; A J Crumbley; F G Spinale
Journal:  Circulation       Date:  1998-05-05       Impact factor: 29.690

5.  Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis.

Authors:  J Travis Hinson; Anant Chopra; Andre Lowe; Calvin C Sheng; Rajat M Gupta; Rajarajan Kuppusamy; John O'Sullivan; Glenn Rowe; Hiroko Wakimoto; Joshua Gorham; Michael A Burke; Kehan Zhang; Kiran Musunuru; Robert E Gerszten; Sean M Wu; Christopher S Chen; Jonathan G Seidman; Christine E Seidman
Journal:  Cell Rep       Date:  2016-12-20       Impact factor: 9.423

6.  Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio.

Authors:  M Pauschinger; D Knopf; S Petschauer; A Doerner; W Poller; P L Schwimmbeck; U Kühl; H P Schultheiss
Journal:  Circulation       Date:  1999-06-01       Impact factor: 29.690

7.  Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism.

Authors:  C G Brilla; C Scheer; H Rupp
Journal:  J Hypertens Suppl       Date:  1997-12

Review 8.  Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.

Authors:  Francis G Spinale
Journal:  Physiol Rev       Date:  2007-10       Impact factor: 37.312

9.  Differential expression of tissue inhibitors of metalloproteinases in the failing human heart.

Authors:  Y Y Li; A M Feldman; Y Sun; C F McTiernan
Journal:  Circulation       Date:  1998-10-27       Impact factor: 29.690

10.  Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy.

Authors:  Ankur Gulati; Andrew Jabbour; Tevfik F Ismail; Kaushik Guha; Jahanzaib Khwaja; Sadaf Raza; Kishen Morarji; Tristan D H Brown; Nizar A Ismail; Marc R Dweck; Elisa Di Pietro; Michael Roughton; Ricardo Wage; Yousef Daryani; Rory O'Hanlon; Mary N Sheppard; Francisco Alpendurada; Alexander R Lyon; Stuart A Cook; Martin R Cowie; Ravi G Assomull; Dudley J Pennell; Sanjay K Prasad
Journal:  JAMA       Date:  2013-03-06       Impact factor: 56.272

View more
  6 in total

Review 1.  Heart failure in single right ventricle congenital heart disease: physiological and molecular considerations.

Authors:  Anastacia M Garcia; Jonathan-Thomas Beatty; Stephanie J Nakano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-28       Impact factor: 4.733

2.  Alteration of cardiolipin biosynthesis and remodeling in single right ventricle congenital heart disease.

Authors:  Anastacia M Garcia; Jessica C McPhaul; Genevieve C Sparagna; Danielle A Jeffrey; Raleigh Jonscher; Sonali S Patel; Carmen C Sucharov; Brian L Stauffer; Shelley D Miyamoto; Kathryn C Chatfield
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-02-14       Impact factor: 4.733

3.  Single-Cell RNA Sequencing and Quantitative Proteomics Analysis Elucidate Marker Genes and Molecular Mechanisms in Hypoplastic Left Heart Patients With Heart Failure.

Authors:  Li Ma; Na Zhou; Rongjun Zou; Wanting Shi; Yuanyuan Luo; Na Du; Jing Zhong; Xiaodong Zhao; Xinxin Chen; Huimin Xia; Yueheng Wu
Journal:  Front Cell Dev Biol       Date:  2021-02-25

4.  Adverse fibrosis remodeling and aortopulmonary collateral flow are associated with poor Fontan outcomes.

Authors:  Andrea Pisesky; Marjolein J E Reichert; Charlotte de Lange; Mike Seed; Shi-Joon Yoo; Christopher Z Lam; Lars Grosse-Wortmann
Journal:  J Cardiovasc Magn Reson       Date:  2021-11-15       Impact factor: 5.364

Review 5.  Complications and management of functional single ventricle patients with Fontan circulation: From surgeon's point of view.

Authors:  Jianrui Ma; Jimei Chen; Tong Tan; Xiaobing Liu; Rong Liufu; Hailong Qiu; Shuai Zhang; Shusheng Wen; Jian Zhuang; Haiyun Yuan
Journal:  Front Cardiovasc Med       Date:  2022-07-29

6.  Adverse effects of Hif1a mutation and maternal diabetes on the offspring heart.

Authors:  Radka Cerychova; Romana Bohuslavova; Frantisek Papousek; David Sedmera; Pavel Abaffy; Vladimir Benes; Frantisek Kolar; Gabriela Pavlinkova
Journal:  Cardiovasc Diabetol       Date:  2018-05-12       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.